Home Prostate / Prostate Cancer NCCN Adds Rucaparib to Prostate Cancer Guidelines

NCCN Adds Rucaparib to Prostate Cancer Guidelines

64
0

Patrick J. Mahaffy, president and CEO of Clovis Oncology

Patrick J. Mahaffy

The National Comprehensive Cancer Network has updated its Clinical Practice Guidelines in Oncology for Prostate Cancer to include new recommendations for the PARP inhibitor rucaparib (Rubraca).1

mutations, including Rubraca, the first PARP inhibitor approved for these patients,” Patrick J. Mahaffy, president and CEO of Clovis Oncology, stated in a press release. “In particular, in the current COVID-19 environment, many patients would prefer to avoid chemotherapy, which requires frequent clinical visits, in favor of an oral agent that can be delivered directly to and taken at home.”

In the international, multicenter, open-label TRITON2 study, investigators enrolled male patients with mCRPC associated with 1 of 13 homologous recombination repair (HRR) gene alterations. Patients had disease progression on androgen receptor–directed therapy and 1 prior taxane-based chemotherapy. Additionally, they had an ECOG performance status of 0 or 1 and could not have received a prior PARP inhibitor, mitoxantrone, cyclophosphamide, or platinum-based chemotherapy.


… to read the full story

https://www.onclive.com/web-exclusives/nccn-adds-rucaparib-to-prostate-cancer-guidelines

This site uses Akismet to reduce spam. Learn how your comment data is processed.